Last updated on July 2019

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Partial Onset Seizures | Pediatric Epileptic Syndrome
  • Age: Between 1 - 18 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Male or female participants. Cohort 1: age 1 month to less than 18 years; Cohort 2: age 1 month to less than 2 years.
  • Have a diagnosis of epilepsy with a pediatric epileptic syndrome (Cohort 1) or epilepsy with partial-onset seizures (POS) with or without secondary generalization (Cohort 2).
  • Have had 4 or more seizures during the 4-week screening/baseline period.
  • Have had brain imaging (example, magnetic resonance imaging [MRI] scan or computed tomography [CT] [or ultrasound for less than 1 year old]) before screening visit that ruled out a progressive cause of epilepsy.
  • Currently maintained on stable doses of 1 to a maximum of 4 approved antiepileptic drugs (AEDs).

Exclusion Criteria:

  • Current or history of pseudo-seizures (psychogenic nonepileptic seizures) within approximately 5 years before screening visit.
  • Have a history of status epilepticus that required hospitalization within 6 months before screening visit.
  • Have an unstable psychiatric diagnosis that may confound participants' ability to participate in the study or that may prevent completion of the protocol specified tests (example, significant suicide risk, including suicidal behavior and ideation within 6 months before screening visit 1, current psychotic disorder, acute mania).
  • Any suicidal ideation with intent with or without a plan within 6 months before randomization visit (answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the C-SSRS) in participants aged 6 and above or based on the opinion of the Investigator for participants less than 6 years.
  • Are scheduled or confirmed or both to have epilepsy surgery within 6 months after screening visit ; however, those who have previously documented "failed" epilepsy surgery will be allowed.
  • Have a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors.
  • Intermittent use of benzodiazepines for any indications other than epilepsy (eg, anxiety/sleep disorders) within 1 month before screening visit. Benzodiazepines used as rescue medication for seizure control are allowed.
  • A vagal nerve stimulator (VNS), responsive neurostimulator (RNS), or deep brain stimulator (DBS) implanted less than 5 months before screening visit or changes in parameter less than 4 weeks before screening visit (or thereafter during the study).
  • Use of perampanel within 30 days before screening visit, or perampanel was discontinued due to adverse reactions (perampanel-related) or lack of efficacy in case of previous exposure.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.